SERENTIL
LOE ApproachingNDAORALCONCENTRATE
Approved
Jan 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an oral concentrate small-molecule antipsychotic approved in 1972 for psychiatric indications. The drug's specific mechanism of action and approved indications are not currently documented in available data. This legacy antipsychotic represents a foundational therapeutic class in psychopharmacology.
LOE Approaching
Moderate competitive pressure (30/100) suggests declining market position; brand team is likely in maintenance or transition mode with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERENTIL represents a mature-stage career opportunity focused on defensive market strategy, margin preservation, and managing the commercial transition as loss of exclusivity approaches. Roles are primarily tactical sales and marketing positions rather than strategic innovation or development roles.
Brand ManagerProduct Manager
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.